RE:RE:RE:SplitWe've always known it takes a physician prescription for these tests. This is cancer testing man, not tooth whitener you buy at your grocery store. Check our website for purchasing tests and it always references a prescription by a physician. What Tripp was talking about was that physician practices have been closed and the ones that are open aren't handling cancer testing like they used to because they are hyper focused on emergencies and covid only. Hospitals are under lockdown just the same as everything else, limited staff, limited patients, limited functions for all of them, so getting Aristotle out there en mass for enormous uptake was always going to be a challenge during covid. So how do you get a prescription for a non covid, non emergency cancer test during covid lockdowns? Tripp went right to the source, a cancer company of oncologists that only deal with cancer, that deal in early diagnosis and intervention they're. they're still open because of the telehealth angle, they're still needing tests, and people will come to them because Hospitals across the world are turning them away. And what's more is that we now have multiple revenue streams, both companies should make each other stronger. People will come to them because of Aristotle, and people will come to us because of our path forward after diagnosis through the oncologists and the c.o.c. protocol. always saw this as the next logical step anyway, maybe they wouldn't have done it so soon but during covid it was probably the only sound option. I'm game
RelevantStock wrote: Just to be clear, there's never been a change of direction. Tripp knew that all along he even invited us to educate ourselves in a recent interview about how the regulations of cancer tests in the US. But he never thought it would be good to inform shareholders before Aristotle, neither his institutionnal investors afaik, that were fighting hard against the shorts to prepare a breakout for the launch that was almost a non event. I couldn't believe it.
davewho wrote: the sp did pretty well after the last RS as I recall. It was the botched release of Aristotle, the unknowns around the Care deal and the change of direction of how to market Aristotle that messed things up. Plus the downgrade didn't help.